ITOS

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its EOS-984, a potentially first-in-class small molecule, focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1, a dominant transporter of extracellular adenosine, expressed on intratumoral T cells, which allows adenosine entry into the cell, disturbing T cell metabolism, expansion, effector function, and survival. It is also developing EOS-215, a potential best-in-class monoclonal antibody which antagonizes the triggering receptor expressed on myeloid cells 2.

Wall Street analysts forecast ITOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITOS is 10.41 USD with a low forecast of 8.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Iteos Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

Iteos Therapeutics Inc. EPS for the last quarter amounts to -1.81 USD, increased 905.56 % YoY.

Iteos Therapeutics Inc (ITOS) has 173 emplpoyees as of August 18 2025.

Today ITOS has the market capitalization of 446.92M USD.